{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:10:59Z","timestamp":1772158259232,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,16]]},"DOI":"10.7759\/cureus.86106","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T07:19:28Z","timestamp":1750058368000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Medical Therapies on Cardiovascular Risk Factors in Acromegaly"],"prefix":"10.7759","author":[{"given":"Robert","family":"Wekesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sriradha","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Alhiraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-17","article-title":"Acromegaly","volume":"3","author":"Chanson P","year":"2008","unstructured":"Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008, 3:17. 10.1186\/1750-1172-3-17","journal-title":"Orphanet J Rare Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28722","article-title":"A comprehensive review of four clinical practice guidelines of acromegaly","volume":"14","author":"Ogedegbe OJ","year":"2022","unstructured":"Ogedegbe OJ, Cheema AY, Khan MA, et al..  A comprehensive review of four clinical practice guidelines of acromegaly. Cureus. 2022, 14:e28722. 10.7759\/cureus.28722","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00028","article-title":"Cardiometabolic risk in acromegaly: a review with a focus on pasireotide","volume":"11","author":"Puglisi S","year":"2020","unstructured":"Puglisi S, Ferra\u00f9 F, Ragonese M, et al.. Cardiometabolic risk in acromegaly: a review with a focus on pasireotide. Front Endocrinol (Lausanne). 2020, 11:28. 10.3389\/fendo.2020.00028","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.01985.x","article-title":"Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass","author":"Vitale G","unstructured":"Vitale G, Galderisi M, Pivonello R, et al.. Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass. 2004. 10.1111\/j.1365-2265.2004.01985.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.11.007","article-title":"Diagnosis and treatment of acromegaly: an update","volume":"97","author":"Ershadinia N","year":"2022","unstructured":"Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly: an update. Mayo Clin Proc. 2022, 97:333-46. 10.1016\/j.mayocp.2021.11.007","journal-title":"Mayo Clin Proc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret L","year":"2011","unstructured":"Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011, 96:1327-35. 10.1210\/jc.2010-2443","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael JD","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nu\u00f1o M, et al.. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014, 99:1825-33. 10.1210\/jc.2013-3757","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha MR","year":"2013","unstructured":"Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab. 2013, 24:238-46. 10.1016\/j.tem.2012.11.007","journal-title":"Trends Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron PJ","year":"2014","unstructured":"Caron PJ, Bevan JS, Petersenn S, et al.. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014, 99:1282-90. 10.1210\/jc.2013-3318","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-016-0096-8","article-title":"Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study","volume":"16","author":"Bronstein MD","year":"2016","unstructured":"Bronstein MD, Fleseriu M, Neggers S, et al.. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr Disord. 2016, 16:16. 10.1186\/s12902-016-0096-8","journal-title":"BMC Endocr Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03620.x","article-title":"A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly","volume":"71","author":"Trainer PJ","year":"2009","unstructured":"Trainer PJ, Ezzat S, D'Souza GA, et al.. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009, 71:549-57. 10.1111\/j.1365-2265.2009.03620.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely AJ","year":"2012","unstructured":"van der Lely AJ, Biller BM, Brue T, et al.. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012, 97:1589-97. 10.1210\/jc.2011-2508","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina A","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, et al.. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020, 21:667-78. 10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","author":"Holdaway IM","unstructured":"Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. 2004. 10.1210\/jc.2003-031199"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2259","article-title":"Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk","volume":"99","author":"Reyes-Vidal C","year":"2014","unstructured":"Reyes-Vidal C, Fernandez JC, Bruce JN, et al.. Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J Clin Endocrinol Metab. 2014, 99:4124-32. 10.1210\/jc.2014-2259","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","article-title":"Systematic reviews of etiology and risk","author":"Maola S","year":"2020","unstructured":"Maola S, Munn Z, Tufanaru C. Systematic reviews of etiology and risk. JBI Man Evi Syn. 2020,","journal-title":"JBI Man Evi Syn"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"Barkan AL","year":"2005","unstructured":"Barkan AL, Burman P, Clemmons DR, et al.. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005, 90:5684-91. 10.1210\/jc.2005-0331","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2570","article-title":"Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control","volume":"95","author":"Berg C","year":"2010","unstructured":"Berg C, Petersenn S, Lahner H, et al.. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab. 2010, 95:3648-56. 10.1210\/jc.2009-2570","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1797-8","article-title":"Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bic\u00eatre cohort, and review of the literature","author":"Briet C","unstructured":"Briet C, Ilie MD, Kuhn E, et al.. Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bic\u00eatre cohort, and review of the literature. Endocrine. 2019. 10.1007\/s12020-018-1797-8","journal-title":"Endocrine"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-0895-8","article-title":"Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly","volume":"53","author":"Schmid HA","year":"2016","unstructured":"Schmid HA, Brue T, Colao A, et al.. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine. 2016, 53:210-9. 10.1007\/s12020-016-0895-8","journal-title":"Endocrine"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02711-3","article-title":"Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant","volume":"73","author":"Chiloiro S","year":"2021","unstructured":"Chiloiro S, Giampietro A, Visconti F, et al.. Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine. 2021, 73:658-66. 10.1007\/s12020-021-02711-3","journal-title":"Endocrine"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao A","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, et al.. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014, 99:791-9. 10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial","volume":"95","author":"Petersenn S","year":"2010","unstructured":"Petersenn S, Schopohl J, Barkan A, et al.. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010, 95:2781-9. 10.1210\/jc.2009-2272","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0679-6","article-title":"Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response","volume":"51","author":"Helseth R","year":"2016","unstructured":"Helseth R, Carlsen SM, Bollerslev J, et al.. Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response. Endocrine. 2016, 51:298-307. 10.1007\/s12020-015-0679-6","journal-title":"Endocrine"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1546","article-title":"Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study","volume":"94","author":"Colao A","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M, et al.. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab. 2009, 94:528-37. 10.1210\/jc.2008-1546","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0941","article-title":"Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study","volume":"94","author":"Colao A","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M, et al.. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009, 94:3746-56. 10.1210\/jc.2009-0941","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13285","article-title":"Glucose and lipid levels with lanreotide autogel 120 mg in treatment-na\u00efve patients with acromegaly: data from the PRIMARYS study","volume":"86","author":"Caron PJ","year":"2017","unstructured":"Caron PJ, Petersenn S, Houchard A, et al.. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-na\u00efve patients with acromegaly: data from the PRIMARYS study. Clin Endocrinol (Oxf). 2017, 86:541-51. 10.1111\/cen.13285","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03181.x","article-title":"Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly","volume":"69","author":"Delaroudis SP","year":"2008","unstructured":"Delaroudis SP, Efstathiadou ZA, Koukoulis GN, et al.. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol (Oxf). 2008, 69:279-84. 10.1111\/j.1365-2265.2008.03181.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.03996.x","article-title":"Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues","volume":"75","author":"Tzanela M","year":"2011","unstructured":"Tzanela M, Vassiliadi DA, Gavalas N, et al.. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol (Oxf). 2011, 75:96-102. 10.1111\/j.1365-2265.2011.03996.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1704","article-title":"Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors","volume":"91","author":"Ronchi CL","year":"2006","unstructured":"Ronchi CL, Varca V, Beck-Peccoz P, et al.. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab. 2006, 91:121-8. 10.1210\/jc.2005-1704","journal-title":"J Clin Endocrinol Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12455","article-title":"The beneficial effect of acromegaly control on blood pressure values in normotensive patients","volume":"81","author":"Sardella C","year":"2014","unstructured":"Sardella C, Urbani C, Lombardi M, et al.. The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clin Endocrinol (Oxf). 2014, 81:573-81. 10.1111\/cen.12455","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0240-9","article-title":"Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides","volume":"13","author":"Andreassen M","year":"2010","unstructured":"Andreassen M, Faber J, Kj\u00e6r A, et al.. Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides. Pituitary. 2010, 13:329-36. 10.1007\/s11102-010-0240-9","journal-title":"Pituitary"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-024-01403-1","article-title":"The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study","volume":"27","author":"De Alcubierre D","year":"2024","unstructured":"De Alcubierre D, Feola T, Cozzolino A, et al.. The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study. Pituitary. 2024, 27:416-27. 10.1007\/s11102-024-01403-1","journal-title":"Pituitary"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-007-0062-6","article-title":"The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly","volume":"11","author":"De Marinis L","year":"2008","unstructured":"De Marinis L, Bianchi A, Mazziotti G, et al.. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary. 2008, 11:13-20. 10.1007\/s11102-007-0062-6","journal-title":"Pituitary"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03339-1","article-title":"Secondary diabetes mellitus in acromegaly","volume":"81","author":"Moustaki M","year":"2023","unstructured":"Moustaki M, Paschou SA, Xekouki P, et al.. Secondary diabetes mellitus in acromegaly. Endocrine. 2023, 81:1-15. 10.1007\/s12020-023-03339-1","journal-title":"Endocrine"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2276","article-title":"The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly","volume":"92","author":"Lindberg-Larsen R","year":"2007","unstructured":"Lindberg-Larsen R, M\u00f8ller N, et al.. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab. 2007, 92:1724-8. 10.1210\/jc.2006-2276","journal-title":"J Clin Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti G","year":"2009","unstructured":"Mazziotti G, Floriani I, Bonadonna S, et al.. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009, 94:1500-8. 10.1210\/jc.2008-2332","journal-title":"J Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","author":"M\u00f8ller N","year":"2009","unstructured":"M\u00f8ller N, J\u00f8rgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009, 30:152-77. 10.1210\/er.2008-0027","journal-title":"Endocr Rev"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01460.x","article-title":"Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly","volume":"56","author":"Parkinson C","year":"2002","unstructured":"Parkinson C, Drake WM, Wieringa G, et al.. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf). 2002, 56:303-11. 10.1046\/j.1365-2265.2002.01460.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa014","article-title":"High-performance liquid chromatography-mass spectrometry-based lipid metabolite profiling of acromegaly","volume":"105","author":"Wang M","year":"2020","unstructured":"Wang M, Guo S, He M, et al.. High-performance liquid chromatography-mass spectrometry-based lipid metabolite profiling of acromegaly. J Clin Endocrinol Metab. 2020, 105:10.1210\/clinem\/dgaa014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13762","article-title":"Somatostatin receptor ligands suppressed proliferation and lipogenesis in 3T3-L1 preadipocytes","volume":"131","author":"Zhao Z","year":"2022","unstructured":"Zhao Z, Gong F, Duan L, et al.. Somatostatin receptor ligands suppressed proliferation and lipogenesis in 3T3-L1 preadipocytes. Basic Clin Pharmacol Toxicol. 2022, 131:174-88. 10.1111\/bcpt.13762","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02273.x","article-title":"The effect of atorvastatin on serum lipoproteins in acromegaly","volume":"62","author":"Mishra M","year":"2005","unstructured":"Mishra M, Durrington P, Mackness M, et al.. The effect of atorvastatin on serum lipoproteins in acromegaly. Clin Endocrinol (Oxf). 2005, 62:650-5. 10.1111\/j.1365-2265.2005.02273.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-13-2-64","article-title":"Cardiovascular disease in acromegaly","volume":"13","author":"Sharma MD","year":"2017","unstructured":"Sharma MD, Nguyen AV, Brown S, Robbins RJ. Cardiovascular disease in acromegaly. Methodist Debakey Cardiovasc J. 2017, 13:64-7. 10.14797\/mdcj-13-2-64","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0263-2","article-title":"Is left ventricular dysfunction reversed after treatment of active acromegaly?","volume":"14","author":"Toumanidis ST","year":"2011","unstructured":"Toumanidis ST, Evangelopoulos ME, Ilias I, et al.. Is left ventricular dysfunction reversed after treatment of active acromegaly?. Pituitary. 2011, 14:75-9. 10.1007\/s11102-010-0263-2","journal-title":"Pituitary"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2547","article-title":"Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis","volume":"92","author":"Maison P","year":"2007","unstructured":"Maison P, Tropeano AI, Macquin-Mavier I, et al.. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007, 92:1743-7. 10.1210\/jc.2006-2547","journal-title":"J Clin Endocrinol Metab"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3072","article-title":"A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy","volume":"98","author":"Annamalai AK","year":"2013","unstructured":"Annamalai AK, Webb A, Kandasamy N, et al.. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab. 2013, 98:1040-50. 10.1210\/jc.2012-3072","journal-title":"J Clin Endocrinol Metab"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1587","article-title":"Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance","volume":"92","author":"Pivonello R","year":"2007","unstructured":"Pivonello R, Galderisi M, Auriemma RS, et al.. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab. 2007, 92:476-82. 10.1210\/jc.2006-1587","journal-title":"J Clin Endocrinol Metab"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-0995-5","article-title":"Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly","volume":"55","author":"Auriemma RS","year":"2017","unstructured":"Auriemma RS, Grasso LF, Galdiero M, et al.. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine. 2017, 55:872-84. 10.1007\/s12020-016-0995-5","journal-title":"Endocrine"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09560-x","article-title":"Acromegaly, inflammation and cardiovascular disease: a review","volume":"21","author":"Wolters TL","year":"2020","unstructured":"Wolters TL, Netea MG, Riksen NP, et al.. Acromegaly, inflammation and cardiovascular disease: a review. Rev Endocr Metab Disord. 2020, 21:547-68. 10.1007\/s11154-020-09560-x","journal-title":"Rev Endocr Metab Disord"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-27302011000700006","article-title":"Hypertension-related factors in patients with active and inactive acromegaly","volume":"55","author":"Fedrizzi D","year":"2011","unstructured":"Fedrizzi D, Rodrigues TC, Costenaro F, et al.. Hypertension-related factors in patients with active and inactive acromegaly. Arq Bras Endocrinol Metabol. 2011, 55:468-74. 10.1590\/s0004-27302011000700006","journal-title":"Arq Bras Endocrinol Metabol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/354018-impact-of-medical-therapies-on-cardiovascular-risk-factors-in-acromegaly","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T07:19:28Z","timestamp":1750058368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/354018-impact-of-medical-therapies-on-cardiovascular-risk-factors-in-acromegaly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.86106","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}